RAMM Pharma
A leader in the research and development of cannabinoid pharmaceutical formulations..
Launch date
Employees
Market cap
AUD2.7m
Enterprise valuation
(AUD67k) (Public information from Sep 2024)
Share price
CAD0.02 RAMM.CN
Toronto Ontario (HQ)
Financials
Estimates*
| CAD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | 8.3m | 5.6m | 5.4m | 4.1m | 3.9m | 5.1m |
| % growth | - | (33 %) | (3 %) | (24 %) | (5 %) | 30 % |
| EBITDA | (<1m) | (2.1m) | (6.8m) | (6.3m) | (6.6m) | (5.2m) |
| % EBITDA margin | (3 %) | (37 %) | (125 %) | (154 %) | (169 %) | (103 %) |
| Profit | (<1m) | (6.8m) | (7.4m) | (7.1m) | (21.0m) | (7.7m) |
| % profit margin | (8 %) | (122 %) | (136 %) | (173 %) | (538 %) | (152 %) |
| EV / revenue | - | - | 5.0x | 9.8x | 4.0x | 0.3x |
| EV / EBITDA | - | - | -4.0x | -6.4x | -2.3x | -0.2x |
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | CAD35.3m | Late VC |
| N/A | N/A | IPO | |
* | N/A | $1.0m | Post IPO Equity |
* | N/A | CAD1.0m | Private Placement non VC |
| Total Funding | AUD40.0m | ||
